Clinical Trials Browser

Phase 4 × INDUSTRY × Uterine Cervical Neoplasms × Clear all

Urogenital Diseases, Uterine Cervical Diseases, Uterine Cervical Neoplasms, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Female, Neoplasms by Site, Uterine Diseases, Uterine Neoplasms, Female Urogenital Diseases

NCT03629886 2024-03-15

Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study

Phase 4 Completed

6,051 enrolled 11 charts

Gynecologic

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms

NCT05426148 2022-06-29

Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female

Phase 4 Completed

540 enrolled

Gynecologic

Persistent Infection, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01031069 2020-07-21

Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

Phase 4 Completed

873 enrolled 34 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT00534638 2019-11-15

Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents

Phase 4 Completed

34,412 enrolled 21 charts

Gynecologic

Uterine Cervical Neoplasms, Papillomavirus Infections

NCT01544478 2018-11-28

V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)

Phase 4 Completed

1,030 enrolled 5 charts

Gynecologic

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Adenocarcinoma in Situ

Clinical Trials

Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study

Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female

Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents

V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)